Erysipelothrix rhusiopathiae continues to be a significant concern in veterinary health, impacting livestock productivity worldwide. This bacterium particularly affects pigs, potentially leading to economic losses for farmers due to ill health and lowered production rates. The introduction of Eryseng, an inactivated bacterial vaccine aimed at immunizing suidae against Erysipelothrix rhusiopathiae, represents a noteworthy stride in preventive veterinary care. The European Union granted its authorization for Eryseng in October 2014, and subsequent evaluations underscore its effectiveness in protecting herds and ensuring animal well-being.
Current Status and Regulatory Information
Authorised for use across the European Union, Eryseng offers significant promise in combatting Erysipelothrix rhusiopathiae infections among pigs. This inactivated vaccine developed using the strain R32E11 aims to bolster immunity against the bacterium, reducing incidence rates. The European Medicines Agency (EMA) has kept its stakeholders informed through consistent updates, with the latest information released in September 2025. Regulatory processes have been thorough, reflecting a commitment to high safety and effectiveness standards.
Highlights from the Committee for Veterinary Medicinal Products
The Committee for Veterinary Medicinal Products (CVMP), over several years, has held meetings highlighting Eryseng’s progress. Recent discussions in November 2023 reaffirmed the vaccine’s role and addressed any ongoing developments in its application. Through these meetings, the CVMP ensures that Eryseng remains a viable and trusted option for livestock veterinarians and farmers.
Consider the following insights:
- The CVMP monitors procedural updates and scientific advancements of Eryseng rigorously.
- The vaccine’s effectiveness has been validated through extensive testing and regular evaluation post-authorization.
Bringing Erysengel to the forefront offers substantial preventive benefits for European farmers striving against Erysipelothrix rhusiopathiae infections. The vaccine continues to evolve alongside scientific advancements and comprehensive regulatory oversight, ensuring its efficacy and safety for the intended purposes. Livestock veterinarians should consider integrating it into their disease prevention strategies to improve herd health and productivity.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
